A Multicenter, Prospective, Randomized, Open-label, Intra-subject Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated With Generalized Epidermolysis Bullosa [Estudio multicentrico, prospectivo, aleatorizado, abierto, de control intraindividual, sobre la eficacia y seguridad de ABH001 para el tratamiento de heridas cutaneas cronicas estancadas asociadas con la epidermolisis bullosa generalizada]

Trial Profile

A Multicenter, Prospective, Randomized, Open-label, Intra-subject Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated With Generalized Epidermolysis Bullosa [Estudio multicentrico, prospectivo, aleatorizado, abierto, de control intraindividual, sobre la eficacia y seguridad de ABH001 para el tratamiento de heridas cutaneas cronicas estancadas asociadas con la epidermolisis bullosa generalizada]

Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs ABH 001 (Primary)
  • Indications Epidermolysis bullosa
  • Focus Registrational; Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 01 Nov 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 Oct 2013 Planned number of patients changed from 1 to 26 as reported by European Clinical Trials Database.
    • 19 Oct 2013 New source identified and integrated (European Clinical Trials Database, EudraCT2012-001815-21).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top